ARCANGELO (itAlian pRospective Study on CANGrELOr)
ARCANGELO
Multicentre Observational, Prospective Cohort Study Including Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention Who Receive Cangrelor i.v. Transitioning to Clopidogrel, Prasugrel or Ticagrelor Per os
2 other identifiers
observational
1,005
1 country
30
Brief Summary
The Sponsor implemented a post-authorisation safety study (PASS), category 3, focused in Acute Coronary Syndrome, in order to collect information about the safety of cangrelor in the real clinical practice, evaluating the safety of the transition to all the oral P2Y12 inhibitors (cangrelor, ticagrelor and prasugrel).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2020
30 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 6, 2020
CompletedFirst Posted
Study publicly available on registry
July 15, 2020
CompletedStudy Start
First participant enrolled
October 23, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 17, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
January 17, 2022
CompletedFebruary 20, 2026
February 1, 2026
1.2 years
July 6, 2020
February 19, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Incidence of any haemorrages according to BARC (Bleeding Academic Research Consortium) criteria
The incidence will be calculated as the ratio between the number of patients experiencing at least one event during the 30-day observation period over the total number of evaluable patients.
30 days post-PCI
Secondary Outcomes (8)
Incidence of type 1-2 (mild) bleedings, according to the Bleeding Academic Research Consortium [BARC] criteria
48 hours after PCI
Incidence of type 1-2 (mild) bleedings, according to the Bleeding Academic Research Consortium [BARC] criteria
30 days after PCI
Incidence of type 3-5 (moderate severe) bleedings, according to the Bleeding Academic Research Consortium [BARC] criteria
48 hours after PCI
Incidence of type 3-5 (moderate severe) bleedings, according to the Bleeding Academic Research Consortium [BARC] criteria
30 days after PCI
Incidence of major adverse cardiac events (MACE)
48 hours after PCI
- +3 more secondary outcomes
Eligibility Criteria
Patients with acute coronary syndromes undergoing percutaneous coronary intervention who receive cangrelor i.v. according to the clinical practice
You may qualify if:
- Patients' written informed and privacy consent obtained before or at the end of the PCI procedure according to patients' condition but in any case, prior to collection of any study-related data;
- Male or female patients aged ≥ 18 years;
- Patients with acute coronary syndromes undergoing PCI;
- Patients who are planned to be treated with cangrelor, or who have received treatment with cangrelor.
You may not qualify if:
- Patients with active bleeding or increased risk of bleeding, because of impaired haemostasis and/or irreversible coagulation disorders or due to recent major surgery/trauma or uncontrolled severe hypertension;
- Patients with history of stroke or transient ischaemic attack (TIA);
- Patients with hypersensitivity to the active substance (cangrelor) or to any of its excipients;
- Known pregnancy or breast-feeding female patients;
- Patients with stable angina (SA).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (30)
A.O.U. Riuniti
Ancona, Italy
Ospedale San Donato
Arezzo, Italy
A.O.U. Consorziale Policlinico
Bari, Italy
Ospedale San Bassiano
Bassano del Grappa, Italy
Azienda Ospedaliera San Pio
Benevento, Italy
Ospedale Maggiore
Bologna, Italy
Fondazione Poliambulanza
Brescia, Italy
A.O. Sant'Anna e San Sebastiano
Caserta, Italy
A.O.U. Policlinico-Vittorio Emanuele P.O. Ferrarotto
Catania, Italy
Ospedale SS Annunziata
Cosenza, Italy
ASO Santa Croce e Carle
Cuneo, Italy
A.O.U. Careggi
Florence, Italy
Ospedale Fabrizio Spaziani
Frosinone, Italy
Ospedale S. Andrea
La Spezia, Italy
Ospedale Santa Maria Goretti
Latina, Italy
Fondazione Toscana "G. Monasterio" Ospedale del Cuore G. Pasquinucci
Massa, Italy
Centro Cardiologico Monzino
Milan, Italy
A.O.R.N. A. Cardarelli
Naples, Italy
A.O.U. Federico II
Naples, Italy
A.O. Padova
Padua, Italy
Policlinico San Matteo
Pavia, Italy
Ospedale degli Infermi
Rivoli, Italy
San Camillo Forlanini
Roma, 00152, Italy
Aurelia Hospital
Roma, Italy
Fondazione Policlinico Universitario A. Gemelli
Roma, Italy
A.O.U. Sassari
Sassari, Italy
Ospedale Umberto I
Syracuse, Italy
A.O. Mauriziano
Torino, Italy
Ospedale Santa Chiara
Trento, Italy
Ospedale Ca' Foncello
Treviso, Italy
Related Publications (2)
De Luca L, Calabro P, Chirillo F, Rolfo C, Menozzi A, Capranzano P, Menichelli M, Nicolini E, Mauro C, Trani C, Versaci F, Tomai F, Musumeci G, Di Mario C, Pepe M, Berti S, Cernetti C, Cirillo P, Maffeo D, Talanas G, Ferlini M, Contarini M, Lanzilotti V, Scherillo M, Tarantini G, Muraglia S, Rossini R, Bolognese L; ARCANGELO study group. Use of cangrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Study design and interim analysis of the ARCANGELO study. Clin Cardiol. 2022 Sep;45(9):913-920. doi: 10.1002/clc.23878. Epub 2022 Jun 22.
PMID: 35733352RESULTCapranzano P, Calabro P, Musumeci G, Mario CD, Chirillo F, Rolfo C, Menozzi A, Menichelli M, Maffeo D, Talanas G, Ferlini M, Contarini M, Lanzilotti V, De Luca L. Use of Cangrelor in Older Patients: Findings from the itAlian pRospective Study on CANGrELOr Study. Am J Cardiol. 2025 Apr 1;240:31-37. doi: 10.1016/j.amjcard.2024.12.021. Epub 2024 Dec 21.
PMID: 39716523DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 6, 2020
First Posted
July 15, 2020
Study Start
October 23, 2020
Primary Completion
January 17, 2022
Study Completion
January 17, 2022
Last Updated
February 20, 2026
Record last verified: 2026-02
Data Sharing
- IPD Sharing
- Will not share